



Hea rt fai lu re (HF) is a freque nt chro nic di sea se in el der ly peop le and rep re sen ts a ma jor heal th and eco no mic bur den. The ac cu ra te diag no sis of HF 
and the iden ti fi  ca tion of hi gh ri sk pa tien ts is man da to ry to se le ct the ap prop ria te the ra py and ca re. HF is as so cia ted to car diac re mo de li ng and in-
fl am ma tion and to the re lea se of neu ro hor mo nes. If nat riu re tic pep ti des re main the bio mar ke rs of choi ce for the diag no sis and the prog no sis of HF, 
se ve ral bio mar ke rs re la ted to car diac re mo de li ng and in fl am mation are avai lab le for tes ti ng and may add va luab le in for ma tion for the ri sk es ti ma-
tion of HF pa tien ts and for the se lec tion of the mo st ap prop ria ted the ra py. Fur ther mo re, the que st for new effi   cie nt bio mar ke rs of car diac re mo de-
li ng and in fl am ma tion is still on goi ng and new can di da tes ha ve been iden ti fi ed for a po ten tial use in dai ly cli ni cal prac ti ces. Howe ver, be fo re their 
po ten tial tran sla tion to rou ti ne pa ra me te rs se ve ral chal len ges ran gi ng fo rm the ana lyti cal va li da tion to the co st-eff ec ti ve ne ss es ti mation shou ld be 
con si de red.
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Infl ammation
The bur den of hea rt fai lu re
Hea rt fai lu re (HF) rep re sen ts the ina bi li ty of the 
hea rt to res po nd to the cir cu la to ry de ma nd of the 
or ga ni sm (1). The main cau ses of HF are hyper ten-
sion, is chae mic and val vu lar inju ries whe reas toxic, 
me ta bo lic or ge ne tic ori gi ns are le ss com mon. In 
ad di tion to the ini tial ab nor ma li ty, se con da ry 
chan ges oc cur over the cour se lea di ng to mul ti-or-
gan im pair me nt (2). The pre va len ce of HF is im por-
ta nt and mo re than 20 mil lion peop le wor ldwi de 
are es ti ma ted to suff er from HF (3). HF is in crea si ng 
be cau se of an agei ng po pu la tion, the suc ce ss in 
pro lon gi ng sur vi val in pa tien ts suff e ri ng of co ro-
na ry even ts, and the suc ce ss in pos tpo ni ng co ro-
na ry even ts by eff ec ti ve pre ven tion in tho se at hi-
gh ri sk or tho se who ha ve al rea dy sur vi ved to a fi r-
st eve nt (4). HF ap pea rs al so as a dead ly and cos tly 
di sor der, car ryi ng an ove ra ll wor se prog no sis (5). 
Thus, HF rep re sen ts a ma jor pu blic heal th prob lem 
wi th a hi gh deg ree of mor bi di ty (6). In ad di tion, the 
eco no mi cal im pa ct of HF is tre men dous ly im por ta-
nt for heal thca re syste ms (7). In Uni ted Kin gdom, 
Stewa rt et al. ha ve es ti ma ted that the an nual di re ct 
co st of HF in year 2000 was about 1.9% of the to tal 
expen di tu re of the Na tio nal Heal th Ser vi ce (7).
Car diac hyper trop hy and re mo de li ng
Alte ra tion in the hea rt wor kload lea ds to ma jor 
chan ges in myo car dial struc tu re and fun ction. In-
crea sed wor kload in du ces adap ti ve mec ha nis ms 
main tai ni ng adequa te blood fl ow throu gh the pul-
mo na ry and syste mic cir cu la tio ns. Ul ti ma te ly, pro-
longed car dio vas cu lar stre ss lea ds to myo car dial 
de te rio ra tion and hea rt fai lu re. Car diac re mo de li-
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ng is cha rac te ri zed by car diac hyper trop hy, fi b ro sis 
and in fl am ma to ry pro ce ss. Exer ci se con di tio ni ng, 
whi ch chro ni cal ly in crea ses the hea rt wo rk, lea ds 
to so me degree of myo car dial hyper trop hy. This 
physio lo gic hyper trop hy is cha rac te ri zed by in-
crea ses in bo th len gth and wid th of car dio myo-
cytes, and is re fer red to “pro por tio na l” (8). Pat ho-
lo gi cal myo car dial hyper trop hy is in du ced main ly 
by hyper ten sion, val vu lar dysfun ction and lo ss of 
myo cytes fol lowi ng is che mic da ma ge (9). So me 
ge ne tic al te ra tio ns may al so lead to pat ho lo gi cal 
hyper trop hy (10). At the ear ly sta ges of chro nic 
pres su re over load, the car dio myo cytes hyper trop-
hy is cha rac te ri zed by an in crea se in ce ll si ze and 
sti mu la tion of pro tein synthe sis. The as sem bly of 
sar co me res oc cu rs in pa ral lel, re sul ti ng in wi de ni-
ng of the car diomyo cytes. Typi cal ly in chro nic ar-
te rial hyper ten sion this lea ds to re du ced le ft ven-
tri cu lar vo lu me and in crea sed wa ll thic kne ss, re fer-
red to a con cen tric hyper trop hy (11). The hyper-
trop hy re la ted to the ear ly sta ges of car dio myo-
cytes hyper trop hy is al so cha rac te ri zed by the 
reac ti va tion of the fe tal ge ne prog ram, wi th reac ti-
va tion of β myo sin hea vy chain, α-ac tin and ANP 
ge ne expres sion (12). The expres sion of ot her ge-
nes al rea dy expres sed in the nor mal adu lt myo car-
dium, su ch as BNP and en dot he lin ge nes, are al so 
in crea sed. In mo re ad van ced chro nic sta ges, the 
car diac cham be rs dilate to get her wi th a thin ni ng 
of the ven tri cu lar wa ll. The sar co me res are then or-
ga ni zed in se ries cau si ng ce ll elon ga tion; this lo ng 
stan di ng pro ce ss lea ds to di la tion of the hea rt ca-
vi ties, cha rac te ris tics of the ec cen tric di la tion of HF. 
Hea rt fai lu re is al so cha rac te ri zed by a lo ss of myo-
cytes due to ce ll apop to sis as we ll as prog res si ve 
fi b ro tic pro ces ses. The oc cur ren ce of fi b ro sis is re la-
ted to the pro li fe ra tion of car diac fi b rob las ts, wi th 
si mul ta neous col la gen de po si tion and wi ll con tri-
bu te to the lo ss of car diac fun ction (13-15). Car diac 
re mo de li ng wi ll al so aff e ct elec trop hysio lo gi cal pro-
per ties and con tri bu te to car diac ar r hythmia.
Hea rt fai lu re, neu ro hor mo nal ac ti va tion 
and bio mar ke rs
Mo st of the biomar ke rs wi th po ten tial diag no sis 
and prog no sis ap pli ca tio ns de ri ve from the neu ro-
hor mo nal res pon se to the fai li ng myo car dium. In-
deed, neu ro hor mo nal ac ti va tion plays a sig ni fi  ca-
nt ro le in myo car dial and mul ti-or gan adap ta tio ns 
to HF (16,17). The use of biomar ke rs for the diag no-
sis of pa tien ts sus pec ted of HF is con stan tly rai si ng 
and is now pa rt of dai ly prac ti ces in in dus tria li zed 
coun tries (6,18). Thus, rapid and sen si ti ve tes ts for 
B-type nat riu re tic pep ti de (BNP) and the bio lo gi-
cal ly inac ti ve N-ter mi nal frag me nt (NT-proBNP) are 
rou ti ne ly used and are in clu ded in the ESC gui de li-
nes as the next step beyo nd cli ni cal exa mi na tion, 
ECG, che st-X-ray and ec ho car diog rap hy for the 
clas si fi  ca tion of pa tien ts sus pec ted to pre se nt HF. 
Bio mar ke rs may al so ful fi l com ple men ta ry in for-
ma tion for the eva lua tion of the di sea se se ve ri ty, 
the prog no sis es ti ma tion and for treat me nt se lec-
tion and bio mar ke rs of in fl am ma tion and car diac 
re mo de li ng may pro vi de ad di tio nal in for ma tion to 
nat riu re tic pep ti des tes ti ng (19). As pre vious ly 
men tio ned, the re mo de li ng and fi b ro sis of the 
hea rt plays an im por ta nt ro le in the prog res sion of 
hea rt fai lu re. Biomar ke rs re la ted to car diac hyper-
trop hy, car diac fi b ro sis and re mo de li ng of the 
extra cel lu lar mat rix may provide va luab le in for ma-
tion for the ri sk stra ti fi  ca tion of HF pa tien ts. In fl am-
ma tion is sti mu la ti ng car diac re mo de li ng and fi b-
ro sis and thus par ti ci pa tes in the pat ho ge ne sis and 
prog res sion of HF. The re fo re, bio mar ke rs re la ted 
to the in fl am ma to ry res pon se in HF are in ten si ve ly 
eva lua ted (20). Se ve ral cyto ki nes and bio mar ke rs re-
la ted to the ac ti va tion of neut rop hi ls and mac rop-
ha ges ha ve been in ves ti ga ted for their abi li ty to 
con tri bu te to the ri sk stra ti fi  ca tion of HF pa tien ts.
Bio mar ke rs of in fl am ma tion and car diac re mo-
de li ng al rea dy avai lab le for tes ti ng
Cyto ki nes
The cir cu la ti ng le ve ls of cyto ki nes are en han ced in 
the fai li ng myo car dium (21). Thus, af ter fol lowi ng 
the ini tial hea rt in su lt, the in crea sed pro duc tion of 
proin fl am ma to ry cyto ki nes may chal len ge the sur-
roun di ng tis sue throu gh pro pa ga tion of the in-
fl am ma to ry res pon se and di re ct eff ec ts on the car-
diac myo cyte struc tu re and fun ction (22). Pro-in-
fl am ma to ry cyto ki nes su ch as TNF-α, IL-6, IL-1, and 
IL-18 ap pear to cau se car dio myo cytes apop to sis 
and nec ro sis as we ll as cel ls hyper tro phy. The 
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increa se of cir cu la ti ng cyto ki nes sti mu la ted by HF 
may al so pre di ct lo ng-te rm out co mes (20,22). Tes ti-
ng for cyto ki nes re mains chal len gi ng and diffi   cu lt to 
tran sla te in rou ti ne la bo ra to ries as the as says com-
mon ly used are ba sed on en zyme lin ked im mu no-
sor be nt as say (ELISA) for mat and re main expen si ve.
C-reac ti ve pro tein
The le ve ls of C-reac ti ve pro tein (CRP) are en han ced 
by HF (23). Hig her C-reac ti ve pro tein predicts wor-
se prog no sis in acu te hea rt fai lu re on ly in non in-
fec ted pa tien ts (24). Re ce nt stu dies ha ve re por ted 
a po ten tial ad de d-va lue of CRP for the risk pre dic-
tion of ad ver se cli ni cal even ts in de pen den tly of 
na triu re tic pep ti des (25). The poten tial ad van ta ge 
of CRP tes ti ng is its avai la bi li ty wit hin the ma jo ri ty 
of la bo rato ries throu gh au to ma ted as says.
Mye lo pe roxi da se
Mye lo pe roxi da se (MPO) is a bio mar ker of in fl am-
ma tion and oxi da ti ve stre ss pro du ced by neut rop-
hi ls, mo no cytes, and en dot he lial cel ls. The le ve ls 
of MPO are sti mu la ted by HF and may ap pear as 
an in de pen de nt pre dic tor of mor ta li ty in HF. In a 
stu dy in clu di ng 667 pa tien ts pre sen ti ng to the 
emer gen cy de par tment wi th dyspnea and ob ser-
ved them for 1 year, Reic hlin et al. ha ve mea su red 
the cir cu la ti ng le ve ls of MPO (26). In their stu dy, 
the in crea ses in MPO sig ni fi  can tly con tri bu ted, af-
ter ad jus tme nt for car dio vas cu lar risk fac to rs in 
mul ti va riab le Cox pro por tio nal ha za rd ana lysis, to 
the pre dic tion of 1-year mor ta li ty. MPO tes ti ng was 
fi r st pre sen ted as ELI SAs but nowa days the tes ts 
me nu of so me au to ma ted plat for ms is off e ri ng ac-
ce ss to this pa ra me ter.
Co pep tin
Co pep tin is the C-ter mi nal frag me nt of the ar gi ni-
ne va sop res sin (AVP) (27). Co pep tin le ve ls are en-
han ced in res pon se to stre ss sta tes and in fec tious 
di sea ses. Re ce nt stu dies ha ve de mon stra ted the 
raise of Co pep tin le ve ls in ca se of HF and its po ten-
tial as a mar ker for mor ta li ty and mor bi di ty (28). 
Neu ho ld et al. showed in a co ho rt of mo re than 
700 HF pa tien ts, that co pep tin con cen tra tio ns we-
re re la ted to NYHA fun ctio nal cla ss (29). In ad di-
tion, their stu dy hig hlig hted co pep tin as the mo st 
po te nt sin gle pre dic tor of mor ta li ty in pa tien ts wi-
th NYHA fun ctio nal cla ss II and cla ss III. In the OPTI-
MAAL stu dy, Voo rs et al. ha ve com pa red copep tin 
wi th BNP and NT-proBNP for pre dic tion of dea th 
or a com po si te car dio vas cu lar en dpoi nt in pa tien ts 
who de ve lo ped HF af ter an acu te myo car dial in far-
ction (28). In this stu dy, the ROC curves in di ca ted 
that co pep tin mea su re me nt at ba se li ne was a 
stron ger pre dic tor of mor ta li ty com pa red wi th bo-
th BNP and NT-proBNP (28). The copep tin as say 
can be avai lab le as ELISA but has al so been de ve-
lo ped on an au to ma ted plat fo rm. The re fo re, the 
ac ce ss to copep tin tes ti ng can be pro po sed by so-
me re fe ren ce la bo ra to ries.
En dot he lin
En dot he li n-1 (ET-1) is a 21 ami no aci ds pep ti de and 
is one of the mo st po te nt va so con stric to rs (30). 
ET-1 is synthe si zed as an inac ti ve 212 ami no acid 
prep ro hor mo ne, prep roE T-1. The lat ter is clea ved 
by en do pep ti da ses to the 39–ami no acid, big ET-1 
(31). A fi  nal clea va ge step, per for med by en dot he-
lin con ver ti ng en zyme-1, con ver ts big ET-1 to the 
21–ami no acid pro du ct ET-1. Eff ec ts of ET-1 are me-
dia ted throu gh sti mu la tion of 2 sub types of re cep-
to rs, en dot he lin re cep tor sub type A and en dot he-
lin re cep tor sub type B. ET-1 is pro du ced mos tly in 
en dot he lial cel ls, kid ney and cen tral ner vous sy-
stem (31). Be si de a tran sie nt nit ric oxi de me dia ted 
va so re laxa nt eff e ct, ET-1 is a po te nt va so con stric-
tor. ET-1 exe rt al so di re ct ac tio ns on the hea rt, su ch 
as chro not ro pic and inot ro pic eff ec ts, dec rea se of 
car diac out put, sti mu la tion of myo car dial hyper-
trop hy ET-1 and in duc tion of col la gen synthe sis 
res pon se in car diac fi b rob las ts (32). ET-1 le ve ls are 
in crea sed in HF pa tien ts and Van Be ne den et al. 
ha ve de mon stra ted in se ve re HF pa tien ts (33). Big 
ET-1 and ET-1 are stro ng in de pen de nt pre dic to rs 
of sur vi val in su ch and bet ter for this pur po se than 
nat riu re tic pep ti des or their pro-pep ti des (33). The-
re fo re, the se mar ke rs al low ea si ly iden ti fyi ng a po-
pu la tion wi th hi gh ri sk mor ta li ty eli gib le for mo re 
ag gres si ve the ra pies. As for cyto ki nes, tes ti ng for 
en dot he li ns re mains chal len gi ng and diffi   cu lt to 
tran sla te in rou ti ne la bo ra to ries as the as says are 
ba sed on ELISA for mat and re main expen si ve. 
Thus, on ly so me re fe ren ce la bo ra to ries are ab le to 
pro po se the se bio mar ke rs.
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Fu tu re poten tial bio mar ke rs of car diac 
re mo de li ng
Neop te rin
Neop te rin be lon gs to the che mi cal group known 
as pte ri di nes and is pro du ced by mac rop ha ges 
upon stimu la tion wi th cyto ki nes (34). Neop te rin is 
in di ca ti ve of a pro-in fl am ma to ry im mu ne sta tus 
(34). Neop te rin con cen tra tio ns ha ve been evalua-
ted in HF pa tien ts (35). The aut ho rs ha ve exa mi ned 
a group com po sed of 47 pa tien ts wi th NYHA cla ss 
II and III HF and 20 heal thy vo lun tee rs. HF pa tien ts 
had hig her ba sal con cen tra tio ns of neop te rin than 
the con trol group. In a 12-month ob ser va tion, the 
aut ho rs ha ve al so re por ted a re la tion ship be tween 
neop te rin con cen tra tion and HF prog res sion. In 
anot her stu dy, Sa sa ki et al. ha ve de ter mi ned the 
se rum neop te rin con cen tra tion was mea su red in 
198 pa tients wi th chro nic HF and 62 con trol sub-
jec ts (36). In their stu dy, the con cen tra tion of neop-
te rin was in crea sed wi th ad van ci ng NYHA clas ses. 
Fur ther mo re the hi gh neop te rin group had a sig-
ni fi  can tly hig her in ci den ce of car diac even ts than 
low neop te rin group. Re cen tly, in a lar ger co ho rt 
Na zer et al. ha ve eva lua ted the prog nos tic abi li ty 
of neop te rin tes ti ng (37). Thus, they ha ve as ses sed 
the re la tion ship be tween neop te rin and hos pi ta li-
za tion for HF, and for dea th or HF over a mean fol-
low-up of two yea rs in 3946 sub jec ts wi th acu te 
co ro na ry syndrome and de mon stra ted that neop-
te rin le ve ls are an in de pen de nt pre dic tor of HF 
hos pi ta li za tion, and im pro ve ri sk pre dic tion over 
and abo ve con ven tio nal bio mar ke rs. Hen nig et al. 
ha ve al so re cen tly pro po sed a po ten tial ro le for in-
fl am ma to ry bio mar ke rs and neopte rin for pre dic-
tion of rig ht ven tri cu lar fai lu re af ter im plan ta tion 
of a le ft ven tri cu lar as si st de vi ce. (38). Neop te rin 
tes ti ng is main ly ba sed on ma nual ELISA devo ted 
to re sear ch use. Rai si ng evi den ce may facili ta te the 
tran sla tion of neop te rin tes ti ng to mo re au to ma-
ted ana lyze rs.
Ga lec ti n-3
Ga lec ti n-3, a mem ber of the lec tin fa mi ly, con tai ns 
a car bo hydra te-re cog ni tio n-bin di ng do main (CRD) 
of about 130 ami no aci ds that enab le the spe ci fi c 
bin di ng of β-ga lac to si des (39). Ga lec ti n-3 expres-
sed in the nuc leus, cytop la sm, mi toc hon drion, ce ll 
sur fa ce, and extra cel lu lar spa ce. This pro tein has 
been shown to be in vol ved in ce ll ad he sion, ce ll 
ac ti va tion, ce ll growth and diff e ren tia tion, ce ll cyc-
le, and apop to sis. Re ce nt evi den ce sug ges ts that 
galec ti n-3 is up-re gu la ted in hyper trop hied hear ts 
and may rep re se nt an im por ta nt me dia tor for the 
de ve lop me nt of fibro sis and car diac re mo de li ng 
(39). Van Kim me na de et al. ha ve de te rmined the 
cir cu la ti ng con cen tra tio ns of galec ti n-3 as we ll as 
NT-proBNP and ape lin in 599 pa tients pre sen ti ng 
wi th dyspnea at emer gen cy de par tme nt (40). The 
galec ti n-3 le ve ls we re sig ni fi  can tly hig her in sub-
jec ts wi th HF com pa red wi th tho se wit hout. Re cei-
ver ope ra ti ng cha rac te ris tic ana lysis for mor ta li ty 
pre dic tion showed that, for 60-day prog no sis, ga-
lec ti n-3 had the grea te st area un der the cur ve in 
com pa ri son to NT-proBNP, BNP and ape lin. Shah 
and cowor ke rs have al so mea su red galec ti n-3 in 
pa tien ts pre sen ti ng to ED wi th acu te dyspnea and 
con fi r med this prog no sis abi li ty of galec ti n-3 (41). 
Thus, in their stu dy galec ti n-3 re mai ned a sig ni fi -
ca nt pre dic tor of 4-year mor ta li ty in de pen de nt of 
ec ho car diog rap hic mar ke rs of ri sk. The evi den ce 
re la ted to galec ti n-3 testi ng is ac cu mu la ti ng quic-
kly whi ch is lea di ng to its tran sfer to se ve ral au to-
ma ted ana lyze rs as we ll as poi nt-o f-ca re de vi ces.
GDF-15
Growth diff e ren tia tion fac tor 15 (GDF15), a pro tein 
be lon gi ng to the tran sfor mi ng growth fac tor be ta 
su per fa mi ly, has a role in re gu la ti ng in fl am ma to ry 
and apop to tic pat hways in inju red tis sues and du-
ri ng di sea se pro ces ses. GDF15 ac ts an ti-a pop to tic 
and pro-hyper trop hic in adu lt car dio myo cytes 
(42). The cir cu la ti ng con cen tra tion of GDF-15 was 
mea su red at ba se li ne and at 12 mon ths in pa tien ts 
ran do mi zed in the Val sar tan Hea rt Fai lu re Trial (43). 
Hig her le ve ls of GDF15 we re as so cia ted wi th fea tu-
res of wor se HF and bio mar ke rs of neu ro hor monal 
ac ti va tion, in fl am ma tion, myo cyte inju ry, and re-
nal dysfun ction. Ba se li ne GDF-15 le ve ls we re al so 
as so cia ted wi th the ris ks of mor ta li ty and re mai-
ned in de pen den tly re la ted to mor ta li ty in a Cox 
reg res sion mo del that in clu ded cli ni cal prog nos tic 
va ria bles, B-type nat riu re tic pep ti de, hi gh-sen si ti-
vi ty C-reac ti ve pro tein, and hi gh-sen si ti vi ty tro po-
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nin T. In anot her stu dy hi gh va lues of GDF15 we re 
al so re por ted in HF pa tien ts wi th nor mal ejec tion 
frac tion and may sup po rt diag no sis of HF (44). The 
GDF15 tes ti ng is main ly de vo ted to re sear ch use 
now but may en ter the me nu of so me au to ma ted 
ana lyze rs in a near fu tu re.
Os teo pon tin
Os teo pon tin (OPN) is is a mac rop ha ge-de ri ved, RGD-
con tai ni ng glycop ro tein wi th cyto ki ne-li ke, che mo-
tac tic, and proad he si ve pro per ties. OPN is al so an 
extra cel lu lar struc tu ral pro tein and an or ga nic com-
po ne nt of bo ne. The ove r-expres sion of OPN has 
been re la ted to di la ted car dio myo pat hy (45). The 
myocar dial expres sion of OPN has been des cri bed 
to in crea se wi th the se ve ri ty of HF (46). The plas ma 
le ve ls of OPN ha ve been re la ted to HF, its wor se ni ng 
cour se and the effi   cien cy of le ft ven tri cu lar as sis ted 
de vi ce (47). OPN as says are ba sed on ELISA for mat 
and re main expen si ve. Thus, on ly so me re fe ren ce 
la bo ra to ries are ab le to pro po se the se bio mar ke rs.
Os teop ro te ge rin
Os teop ro te ge rin (OPG) is a cyto ki ne re cep tor and 
a mem ber of the tu mor nec ro sis fac tor re cep tor 
su per fa mi ly. OPG and its li ga nd, the re cep tor ac ti-
va tor of nuc lear fac to r-κB li ga nd (RANKL), are re-
gu la ti ng bo ne re mo de li ng (48). In the Con trol led 
Ro su vas ta tin Mul ti na tio nal Trial in HF (CORONA) 
po pu la tion, ran dom ly as sig ned to 10 mg ro su vas-
ta tin or pla ce bo, OPG le ve ls ad ded in de pen de nt 
pre dic ti ve in for ma tion for the wor se ni ng of HF 
(49). The plas ma OPG le ve ls we re al so as ses sed in 
1,229 pa tien ts wi th HF rec rui ted from 51 cli ni cal 
cen te rs and in clu ded in the Grup po Ita lia no per lo 
Stu dio del la Sop rav vi ven za nel l’In far to Mio car di-
co-Hea rt Fai lu re (GISSI-HF) trial (50). Af ter ad jus-
tme nt for con ven tio nal ri sk mar ke rs, OPG re mai-
ned a sig ni fi  ca nt pre dic tor of dea th. OPG as says 
are ba sed on ELISA for mat and re main expen si ve. 
Thus, on ly so me re fe ren ce la bo ra to ries are ab le to 
propose the se bio mar ke rs.
ST-2
ST2 is an in ter leu ki n-1 re cep tor fa mi ly mem ber wi-
th tran smem bra ne (ST2L) and so lub le (sST2) iso for-
ms (51). ST2 was ori gi nal ly des cri bed in the con text 
of in fl am ma to ry and au toim mu ne di sea ses. Howe-
ver, af ter the iden ti fi  ca tion of IL-33 as the fun ctio-
nal li ga nd for ST2, and con cep tua li za tion of the ro-
le of ST2/IL-33 sig na li ng in car diac re mo de li ng, 
sST2 has emer ged as a po ten tial no vel car dio vas-
cu lar bio mar ker for the pre sen ce of ven tri cu lar bio-
mec ha ni cal over load (52). Reh man et al. ha ve cha-
rac te ri zed ST2 in pa tien ts wi th acu te HF (53). The 
ST2 va lues cor re la ted wi th the se ve ri ty of HF, the 
le ft ven tri cu lar ejec tion frac tion, BNP and NT-
proBNP (53). The ST2 le ve ls at pre sen ta tion we re 
higher amo ng pa tien ts who died by 1 year. In a 
mul ti va riab le Cox mo del con tai ni ng es tab lis hed 
cli ni cal and bioc he mi cal pre dic to rs, ST2 re mai ned 
a pre dic tor of mor ta li ty. When bo th ST2 and nat-
riu re tic pep ti des we re ele va ted, the hig he st ra tes 
of dea th we re obser ved in cu mu la ti ve ha za rd ana-
lysis. Muel ler et al. ha ve al so de ter mi ned plas ma 
con cen tra tio ns of so lub le ST2 in pa tien ts wi th DHF 
at ten di ng the ED (54). In mul ti va riab le Cox pro por-
tio na l-ha zar ds reg res sion ana lyses, an sST2 plas ma 
con cen tra tion in the up per ter ti le at pre sen ta tion 
was a stro ng and in de pen de nt pre dic tor of a ll-cau-
se mor ta li ty af ter one year of fol low-up. ST2 le ve ls 
we re al so eva lua ted in the PRAI SE-2 hea rt fai lu re 
trial. In pa tien ts wi th se ve re chro nic NYHA cla ss III 
to IV HF, the chan ge in ST2 le ve ls is an in de pen de-
nt pre dic tor of sub seque nt mor ta li ty or tran splan-
ta tion (55). ST2 tes ti ng is main ly de vo ted to re sear-
ch use now but may en ter the me nu of so me au to-
ma ted ana lyze rs in a near fu tu re.
Uro cor tin
Uro cor tin (UCN) is a stre ss res pon se pep ti de con-
tai ni ng 40 ami no aci ds be lon gi ng to the cor ti cot-
rop hin re leasing fac tor (CRF) pep ti des fa mi ly (56). 
In 2005, J. Bur nett Jr. has pre sen ted UCN system as 
a com po ne nt of the neu ro hor mo nal res pon se to 
HF (57). UCN is ab le to in du ce hyper trop hy of car-
diac cel ls and immu no his toc he mi cal stu dies ha ve 
de mon stra ted that UCN is expres sed mo re abun-
dan tly in the di sea sed hea rt, di la ted car dio myo-
pat hy and hyper trop hic car dio myo pat hy, than in 
the nor mal hea rt (58,59). In con tra ct, seve ral stu-
died ha ve sug ges ted that UCN treat me nt may ha-
ve he mo dyna mic be ne fi  ts in HF (57,60). Ne ver the-
le ss, the da ta re la ted to the cir cu la ti ng le ve ls of 
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UCN in HF are li mi ted. In deed, Ng and cowor ke rs 
ha ve re por ted that plas ma le ve ls of UCN we re ele-
va ted in HF (61). They al so shown that UCN le ve ls 
in crea sed wi th the NYHA cla ss, es pecial ly in its ear-
ly sta ge, we re ne ga ti ve ly cor re la ted to Nt-proBNP 
(61). We ha ve al so de mon stra ted that the plas ma 
con cen tra tio ns of UCN are in crea sed in HF pa tien ts 
in com pa ri son to heal thy in di vi dua ls (62). Howe ver, 
our re sul ts shown that cir cu la ti ng con cen tra tio ns 
of UCN are in crea sed in HF pa tien ts, in bo th NYHA 
I-II and NYHA III-IV fun ctio nal cla ss sub grou ps and 
we re con tras ti ng wi th Ng et al. Wrig ht et al. ha ve 
re cen tly re por ted that in crea sed UCN le ve ls in HF, 
an in ver se re la tion wi th LVEF and a li near in crea se 
wi th NYHA (63). UCN as says are ba sed on ELISA for-
mat and re main expen sive. Thus, on ly so me re fe-
ren ce la bo ra to ries are ab le to pro po se the se bio-
mar ke rs.
Urotensin-II
Uro ten sin II (UII) is a cyclic un de ca pep ti de, fi r st iso-
la ted from te leo st fi  sh and la ter iden ti fi ed in mam-
ma ls (64). UII pos ses ses mul tip le eff ec ts on the car-
dio vas cu lar system, me dia ted throu gh ac ti va tion 
of G-pro tein coup led re cep to rs. In rat tho ra cic aor-
ta, in cu ba ted in vit ro, UII has been re por ted to be 
the mo st va so con stric tor des cri bed so far. The 
expres sion of UII is in creased in pa tien ts wi th e nd-
sta ge HF in com pa ri son to con tro ls (65). The abi li ty 
of UII to act al so as an au toc ri ne/paracrine fac tor 
par ti ci pa ti ng to car diac hyper trop hy and fi b ro sis is 
al so rai si ng (64,66). In deed, UII has hyper trop hic 
eff e ct on car dio myo cytes and may be im pli ca ted 
in myo car dial fi b ro ge ne sis throu gh in crea sed col-
la gen synthe sis by car diac fi b rob las ts (67). Thus, 
Ric ha rds et al. fou nd that plas ma UII was ele va ted 
in HF pa tien ts, but the stu dy was res tric ted to 
NYHA cla ss IV pa tien ts (68). In su ch a group, UII cor-
re la ted sig ni fi can tly wi th ET-1 and ad re no me dul lin 
but not wi th NT-proBNP. La ter, we ha ve al so 
demon stra ted that the cir cu la ti ng le ve ls of UII are 
in crea sed in HF pa tien ts in com pa ri son to heal thy 
in di vi dua ls (69). Mo reo ver, we showed that plas ma 
UII le ve ls we re re la ted wi th the NYHA fun ctio nal 
clas ses, the LVEF, as we ll as wi th es tab lis hed neur-
hor mo nal bio mar ke rs of HF su ch as BNP and Bi g-
E T-1. The se re sul ts we re in ag ree me nt wi th the wo-
rk of Doug las and co-wor ke rs who ha ve pre vious ly 
re por ted that the myo car dial expres sion of UII cor-
re la ted sig ni fi  can tly wi th le ft ven tri cu lar end dias-
to lic di men sion and LVEF (65). As we ll as for ET-1, 
the ear ly ac ti va tion of UII may par ti ci pa te to myo-
car dial hyper trop hy to pre ve nt the lo ss of systo lic 
fun ction but may al so sti mu la te de le te rious fi b ro-
sis and re mo de li ng of the myo car dium. UII as says 
are ba sed on ELISA for mat and re main expen si ve. 
Thus, on ly some re fe ren ce la bo ra to ries are ab le to 
pro po se the se bio mar ke rs.
Per spec ti ves: se ve ral chal len ges be fo re 
the tran sla tion to dai ly prac ti ces
Our artic le has pre sen ted so me can di da te bio mar-
ke rs re la ted to car diac re mo de li ng and infl am ma-
tion that may sup port the ri sk stra ti fi  ca tion of HF 
pa tien ts. Howe ver, se ve ral chal len ges are pa vi ng 
the way be fo re a po ten tial tran sla tion to dai ly cli ni-
cal prac ti ces (Figu re 1).
Fir st, the se bio mar ke rs shou ld fi r st be ac ces sib le to 
the physi cia ns, ac cu ra te and al low a short tu rn 
arou nd ti me (TAT) of ana lysis (70,71). As il lus tra ted 
in this ar tic le, the evi den ce for emer gi ng bio mar-
ke rs is of ten ob tai ned wi th ma nual tes ti ng. De ve-
lop me nt of mo re au to ma ted, ea si ly ac ces sib le as-
says is then man da to ry for a tran sfer to rou ti ne 
prac ti ces. As exam ple, we can men tion the au to-
ma ted tes ti ng for BNP and NT-proBNP whi ch can 
be ra pid ly per for med on lar ge hos pi ta l-ba sed plat-
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for ms as we ll as on sma ll poi nt-o f-ca re de vi ces 
(70,72). The galec ti n-3 as say wi ll be soon avai lab le 
on au to ma ted plat for ms whi ch may fa ci li ta te its 
use. Howe ver, the ac ce ss to the ma jo ri ty of the bio-
mar ke rs pre sen ted in this ar tic le remai ns li mi ted as 
au to ma ted as says and poi nt-o f-ca re tes ti ng are 
not yet avai lab le.
Se con dly, the as says for these bio mar ke rs shou ld 
al so un der go to a com ple te ana lyti cal eva lua tion 
(73). This eva lua tion wi ll ha ve to de ter mi ne the 
mo st ap prop ria te mea su re me nt mat rix, the as say 
im pre ci sion, the li mi ts of bla nk, the li mi ts of de tec-
tion and quan ti ta tion, as we ll as the li nea ri ty, the 
po ten tial hi gh-do se hook eff e ct, the sto ra ge sta bi-
li ty, the cro ss-reac ti vi ty and the po ten tial in ter fe-
ren ces wi th and ic te rus, li pe mia and he mo lysis. La-
bo ra to ria ns and in vit ro diag nostic ma nu fac tu re rs 
wi ll ha ve al so to joi nt eff or ts to de fi  ne ap prop ria te 
and per so na li zed re fe ren ce and me di cal de ci sion 
li mi ts, to iden ti fy the diag nos tic ti me win dow and 
the mo st ap prop ria te cli ni cal ap pli ca tion of the 
bio mar ke rs and their in tra- and in ter-in di vi dual va-
ria bi li ty (18,23,74).
Thi rd, the ques tion of the poten tial ad ded va lue 
pro vi ded by the bio mar ker wi ll ha ve to be rai sed. It 
is clear that nat riu re tic pep ti des rep re se nt in vit ro 
diag nos tic bloc kbusters, used in dai ly cli ni cal and 
la bo ra to ry prac ti ces, and sup por ti ng the diag no sis 
and prog no sis of HF. The bio mar ker of in fl am ma-
tion and car diac re mo de li ng may he lp for the iden-
ti fi  ca tion of pa tien ts at an in crea sed ri sk of dea th 
in the lo ng te rm. Su ch bio mar ke rs may al so sup-
po rt biomar ke r-gui ded treat me nt (18,19,75). Fur-
ther evi den ce is howe ver requi red be fo re the re-
com men da tion of the mo st ap prop ria te ap pli ca-
tion. Howe ver, the le vel of evi den ce of Ga lec ti n-3, 
GDF15 and Big ET-1 is ri si ng quic kly whi ch may sti-
mu la te their pri me ti me use in a near fu tu re.
Four th, the in teg ra tion of bio mar ke rs from diff e re-
nt pat hways in mul ti mar ker stra te gies (MMS) shou-
ld al so be con si de red (76). Thus, Sa ba ti ne et al. se-
lec ted one mar ker of da ma ge to car diac tis sue, 
cTnI, one mar ker of exces si ve stret chi ng of car diac 
tis sue, BNP, and one mar ker of in fl am ma tion, CRP 
and fou nd in a stu dy of 1,635 pa tien ts that tho se 
wi th one, two, and three ele va ted bio mar ke rs had 
a 2.1-, 3.1-, and 3.7- fo ld in crea se in the ri sk of dea-
th, MI or HF by 6 mon ths (77). Si mi lar ly, in a stu dy 
of no n-ST ele va tion acu te co ro na ry syndro mes 
(no n-ST ACS), Tel lo-Mon to liu et al. stu died the le-
ve ls of TnT, CRP and Nt pro-BNP in 358 pa tien ts 
and fou nd that the MMS stra te gy iden ti fi ed in crea-
sed ri sk of ad ver se even ts at 6 mon ths (78). In ad di-
tion, Zai ris et al. in ves ti ga ted the com bi ned prog-
nos tic va lue of ad mis sion se rum le ve ls of BNP, cTnI 
and hs-CRP in 577 pa tien ts hos pi ta li sed be cau se of 
HF and usi ng a mul ti va ria te Cox reg res sion ana-
lysis con clu ded that in crea si ng num be rs of ele va-
ted bio mar ke rs gra dual ly in crea sed the ri sk of 31-
day car diac dea th (79). A sa me ap proa ch in teg ra ti-
ng plas ma bio mar ke rs that refl e ct de ter mi nan ts of 
mat rix com po si tion iden ti fy the pre sen ce of le ft 
ven tri cu lar hyper trop hy and dias to lic hea rt fai lu re 
ha ve al so been pro po sed (80). The se are ju st the 
ear ly days for MMS and chal len ges su ch as the ap-
prop ria te se lec tion of the bio mar ke rs re main (76).
Fi nal ly, the ques tion of co st eff ec ti ve ne ss of the se 
emer gi ng bio mar ke rs can not be ig no red in the 
cur re nt eva lua tion pro ce ss of la bo ra to ry tes ts and 
re mai ns lar ge ly un co ve red (81,82). In HF, the eco-
no mic im pa ct of BNP tes ti ng has been eva lua ted. 
BNP tes ti ng not on ly re sul ted in a sig ni fi  ca nt re-
duc tion in ti me to treat me nt and re-hos pi ta li za-
tion ra te but al so led to sub stan tial cos ts sa vin gs 
(83,84). For exam ple, Mo ri mo to et al. ha ve con duc-
ted a co st-eff ec ti ve ne ss ana lysis usi ng a Mar kov 
mo del of re gu lar BNP measure me nt in the out pa-
tie nt set ti ng and showed the QALY (qua li ty ad jus-
ted li fe year) to be lon ger for the BNP group and the 
cos ts of treat me nt we re al so lower for the BNP gro-
up (85). Su ch a wo rk re mai ns the re fo re to be ac com-
plis hed for the bio mar ke rs pre sen ted in this ar tic le.
In con clu sion, labo ra to ria ns and physi cia ns shou ld 
con si der the po ten tial be ne fi  ts of bio mar ke rs of in-
fl am ma tion and car diac re mo de li ng for the ri sk 
stra ti fi  ca tion. Ne ver the le ss, mul tip le chal len ges in-
clu di ng the ca re ful eva lua tion of ana lyti cal and cli-
ni cal per for man ces as we ll as their co st-eff ec ti ve-
ne ss shou ld be con si de red be fo re a tran sla tion to 
dai ly prac ti ces.
Po ten tial con fl i ct of in te re st
No ne dec la red.
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Bio loški bi lje zi upa le i re mo de li ra nje mio kar da: pot ra ga za re le van tnim
kan di da ti ma pri stra ti fi  ka ci ji ri zi ka od srčanog za ta je nja još uvi jek tra je
Sažetak
Srčano za ta je nje (en gl. hea rt fai lu re, HF) je čes ta kro nična bo le st kod sta ri jih lju di te pred stav lja ve li ki zdrav stve ni i eko nom ski te ret. Točna di jag-
no za HF i pre poz na va nje oso ba s vi so kim ri zi kom od obo ljenja oba vez ni su ele men ti ka ko bi se mog lo odab ra ti prik lad no li ječenje i skrb. HF je 
po ve za no s re mo de li ra njem mio kar da i upa lom te iz lučiva njem neu ro hor mo na. Nat riu ret ski pep ti di pred stav lja ju pr vi iz bor bio loških bi lje ga za 
di jag no zu i prog no zu HF, no posto ji ne ko li ko dos tup nih bio loških bi lje ga po ve za nih s re mo de li ra njem mio kar da i upa lom ko ji mo gu pružiti do dat-
ne in for ma ci je o proc je ni ri zi ka od HF te po moći pri oda bi ru naj prik lad ni jeg li ječenja. Pot ra ga za no vim učin ko vi tim bio loškim bi lje zi ma re mo de-
liranja mio kar da i upa le još je uvi jek u ti je ku te su pro nađeni no vi kan di da ti za po ten ci jal nu prim je nu u sva kod nev noj kli ničkoj prak si. Međutim, 
pri je nji ho ve po ten ci jal ne tran sfor ma ci je u ru tin ske pa ra met re pot reb no je uze ti u ob zir ne ke iza zo ve ko ji se protežu od ana li tičke va li da ci je do 
proc je ne eko nom ske is pla ti vos ti.
Ključne ri ječi: upa la; re mo de li ra nje; srčano za ta je nje; prog no za; bio loški bi ljeg
